Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Arjun Vasant Balar(NYU Langone Health), Ronald de Wit(Erasmus MC Cancer Institute), Girish S. Kulkarni(University Health Network), Petros Grivas(Seattle Cancer Care Alliance), Edward Uchio(University of California, Irvine), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), M. Roumiguié(Institut universitaire du cancer de Toulouse Oncopole), Ekta Kapadia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Badrinath R. Konety(Allina Health), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Ho Kyung Seo(National Cancer Center), Hiroyuki Nishiyama(University of Tsukuba), Joost L. Boormans(Erasmus MC), Haojie Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Laurence E. Krieger(Unknown), Tara L. Frenkl(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kijoeng Nam(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eric A. Singer(Rutgers Cancer Institute of New Jersey)
Cited by 532
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k